Journal of Alzheimer's Disease & Reports
Journal of Alzheimer's Disease & Reports is an open access peer-reviewed journal from the publishers of Scientific Research and Community (SRC) which publishes articles in the form of written, video and power-point presentations from the arena of Alzheimer's Disease & Reports. The journal focuses to build up accessing the complete content of articles freely from online for reader’s perusal. Articles can be submitted through online from https://srcpublishers.com/Alzheimers-Disease-Reports/user/register or can send through an e-mail with attachment for editor.jadr@onlinescientificresearch.net or alzheimersdisease@onlinescientificresearch.info 0.35 Impact Factor 84.5% Citations 80% Acceptance
Challenges for Family Physicians in Identifying and Preventing Suicidal Behavior
Suicidal Behavior (SB) represents a highly complex health challenge involving biological, psychological, and sociodemographic factors. Its global impact is so significant that it ranks among the top ten causes of death in the general population, causing destabilization within the family unit that often overwhelms the coping mechanisms of those affected
Conrado Ronaliet Alvarez Borges Alvarez Borges
Manuel Ernesto Horta Sánchez Horta Sánchez
Copyright (c) 2026 Journal of Alzheimer's Disease & Reports
Disconnective Surgery for Refractory Multilobar and Hemispheric Epilepsy, A Study of 38 Children
Intractable epilepsy secondary to multilobar and hemispheric pathologies is more prevalent in young children [1]. The negative impact of such seizures on neurological, intellectual and psychosocial development, as well as the risk of irreversible consequences in later life, has been well documented [2-4]. There is also a higher risk of mortality in these patients, often from status epilepticus and sudden unexpected death [5]. As a significant proportion of multilobar and hemispheric epilepsies are due to developmental malformations and in-utero insults, seizures often manifest very early in life. The vulnerability of the developing brain can lead to an increased frequency and severity of seizures, especially epileptic spasms and status epilepticus. The immaturity of the brain also increases risk of seizures being resistant to anticonvulsant medications [6].
A Car Drive Through Water: A Reflection on Rain, Risk, and the Fragility of Urban Life
On 12 December 2025, a short journey to pick up my daughter from school turned into a lived experiment in driving under intense tropical rainfall and sudden flash flooding in Kuala Lumpur. What began as dark clouds above Wisma Methodist at Jalan Hang Jebat developed into a heavy downpour that followed us from the school gate to the entrance of the MEX highway via Jalan Sungai Besi. In this reflection, I weave together my embodied experience of reduced visibility, flooded junctions and the anxious task of protecting a child in the passenger seat with empirical findings from recent research on rain, traffic flow, waterlogging, and vehicle stability. Studies from transportation engineering and flood-risk science show how rainfall intensity, ponding depth, and driver decision-making interact to slow traffic, destabilise vehicles and increase accident severity in urban settings. At the same time, climate-driven increases in intense rainfall expose the limits of drainage and road infrastructure and force cities to rethink how they monitor, design and manage roads under water. My simple question on that evening—“Which lane will still be passable for this old car?”—connects directly to deeper scientific and ethical questions about urban resilience, equity and the everyday vulnerability of families moving through a flooded city.
Heavy Rainfall, Flash Floods, Urban Ecology, Hydrological Stress, Personal Reflection
Remembering Alzheimer’s Legacy: 110 Years since the Passing of Alois Alzheimer
Background: Alzheimer’s disease (AD), first identified by Alois Alzheimer in 1906, is a neurodegenerative disorder characterized by amyloid plaques and neurofibrillary tangles. While Alzheimer’s findings were pivotal, Emil Kraepelin classified AD, Oskar Fischer described similar pathology, and Gheorghe Marinescu’s early work on senile plaques contributed to its understanding. Despite extensive research, AD remains incurable, with its pathophysiology still under investigation. Methods: For this historical and medical review, we systematically explored academic databases like PubMed and Google Scholar, prioritizing original works by Alzheimer, Kraepelin, Fischer, and Marinescu alongside modern interpretations. Our analysis covered neuropathological studies, advancements in imaging, and evolving diagnostic criteria while also considering the historical and scientific contexts that shaped their recognition. Results: While Alzheimer is credited with identifying the disease, Fischer’s 1907 work offered a more detailed analysis of amyloid plaques but was overlooked due to historical biases. Marinescu’s 1892 study on neuroglial nodules predated Alzheimer’s findings but was not initially linked to dementia, while Kraepelin’s 1910 classification secured AD’s place in medical literature. Modern imaging techniques have confirmed these early discoveries, yet effective treatments remain elusive. Conclusion: Alzheimer’s disease remains one of the greatest challenges in modern medicine. While the scientific understanding of its pathology has advanced considerably since the early 20th century, the disease continues to evade definitive treatment. Reflecting on the historical roots of AD research underscores the importance of continued innovation and interdisciplinary collaboration in the quest for better diagnostic and therapeutic strategies.
Alzheimer’s Disease, History of Neurology, Emil Kraepelin, Oskar Fischer, Gheorghe Marinescu, Amyloid Plaques, Neurofibrillary Tangles, Dementia, Neurodegeneration, Medical History, Neuropathology
Improvement in EEG-Derived Functional Brain Age During a 4-Week Biophoton Therapy Intervention in 5 Patients with Alzheimer’s Disease – A Case Report
Background: Alzheimer’s disease (AD) is associated with progressive cognitive impairment and characteristic electrophysiological alterations on Electroencephalography (EEG). EEG-derived functional brain age, integrating quantitative EEG (qEEG) and Event-Related Potential (ERP) features, has emerged as a surrogate marker of neurophysiological aging that may diverge from chronological age in neurodegenerative conditions. Methods: This report describes a longitudinal case series of five patients with mild to moderate Alzheimer’s disease who underwent serial qEEG assessments during a 4-week biophoton therapy intervention. EEG recordings were obtained at baseline and at follow-up time points ranging from 2 to 6 weeks. Functional brain age was calculated using a fixed-weight composite model incorporating posterior alpha rhythm integrity, theta/beta balance, and ERP latency measures related to attention and memory, applied consistently across all time points. Results: At baseline, all patients demonstrated electrophysiological profiles consistent with advanced functional brain aging relative to chronological age. Across cases, longitudinal analysis revealed directionally favorable changes in multiple EEG features, including normalization of posterior alpha rhythms and shortening of ERP latencies. These changes corresponded to reductions in EEG-derived functional brain age ranging from approximately 3 to 8 years over short observation intervals, with variability in magnitude and timing among individuals. Conclusion: This case series demonstrates that qEEG-derived functional brain age is a sensitive and responsive surrogate biomarker capable of capturing short-interval neurophysiological changes in patients with Alzheimer’s disease during biophoton therapy exposure. Although causality and clinical efficacy cannot be inferred from these observations, the findings support further controlled investigation of functional brain age as an objective outcome measure for evaluating non-pharmacologic interventions in neurodegenerative disease.
Alzheimer’s Disease, Electroencephalography, Quantitative EEG, Functional Brain Age, Event-Related Potentials, Brain Aging
Quality of Life of the Caregivers of Patients with Neurodegenerative Disorders, Miami Dade County, Florida
Background: Neurodegenerative disorders, such as Parkinson’s disease, dementia, and Alzheimer’s disease, impact caregivers, influencing their quality of life and mental well-being. Understanding these perceptions is crucial for developing targeted support systems. Purpose: This descriptive study aimed to explore caregivers' experiences with specific neurodegenerative disorders in Miami-Dade County, focusing on psychological distress, coping strategies, and socio-emotional context. Methods: Employing a cross-sectional descriptive survey design, formal and informal caregivers above 18 years old, providing care for patients diagnosed with Alzheimer's Disease, Parkinson's Disease, or dementia, and residing in Miami-Dade County were included. Data collection involved self-reported measures on caregiving characteristics, patients' emotional status, caregiver well-being, and overall health perception. Statistical analysis was accomplished with the IBM-SPSS version 29 (2022) statistical software package. Results: This study presents preliminary findings from a diverse caregiver sample, predominantly female (79%), with varied educational backgrounds. Caregivers reported emotional exhaustion, insomnia, and fatigue. Psychological symptoms showed nuanced associations with educational levels. Detailed demographics reveal marital status (52% married), caregiver types (95% informal), and relationships to care receivers (48% daughters). Frequency and percentage breakdowns are provided for caregiver burdens, patient emotional status, and health assessments, emphasizing the need for targeted support interventions. Conclusion: This study contributes to knowing caregivers' experiences in specific neurodegenerative disorders, emphasizing the need for tailored interventions. While preliminary, these findings highlight the potential impact of educational background on caregiver well-being. Further research and targeted support programs are crucial to improving the overall quality of life for caregivers and patients facing these challenging conditions.
Alzheimer’s Disease Can be Reversed and Even Cured
Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder that remains one of the greatest challenges in modern medicine. Despite extensive research into its underlying molecular, genetic, and environmental mechanisms, no effective cure has yet been identified. From the perspective of the Guan Yin Citta Dharma Door, however, AD is not solely a physical or biochemical condition but one rooted in karmic obstacles and spiritual possession. According to this framework, the deeper causes of AD arise from negative karmic actions, particularly those related to killing and harmful speech. True healing, therefore, must take place at the level of the soul rather than only within the brain. By applying the Buddhist practices taught by Dharma Master Jun Hong Lu, such as making vows, reciting Buddhist scriptures, and performing life liberation, patients can repay karmic debts, help attached spirits ascend, and gradually restore cognitive function. In our previous study, one patient achieved full recovery, and two others showed reversal of AD symptoms. The present study extends these findings with additional cases, suggesting that AD may be reversible and, in some instances, curable through dedicated Dharma practice.
Copyright (c) 2025 Journal of Alzheimer's Disease & Reports
New Anti-Amyloid Therapies - Where we are Wrong and about What do we have to Take Care of
The numbers affected by Alzheimer’s and other dementias has accelerated pace of increasing and still has no tendency to decrease. Effects of the current therapies are quite modest. These effects contribute to negative attitude toward anti dementia drugs, delaying in establishing a diagnosis, postponing of beginning of pharmacological therapy or refusal of using therapy and disbelief in success of other measures like: life style changing, adoption to a new life habit or using non pharmacological therapies. The outcome of these attitudes is significantly faster cognitive decline which is reflected in changes in behavior with more severe episodes of maladaptive behavior that require additional use of medications such as: antipsychotics, hypnotics, benzodiazepines, anti-depressants and anxiolytics. Unfortunately, although non-pharmacological therapies have a real effect in improving the condition of people with dementia, they are not talked about enough. Professional health meetings do not include non-health professionals who do the hard work of improving a patient's condition every day. Also, health professionals do not refer patients to non-pharmacological therapy although there are science researches which prove efficiency. We want to believe that this is because there are few professional institutions that deal with non-pharmacological interventions, but also experts who have the knowledge, skills and tools for that job. National health and social care systems that either do not recognize these services as useful therapies or offer these services under limited conditions certainly contribute to this serious deficiency. This issue also shows the non-harmonious functioning of the health and social sectors, although non-pharmacological interventions has potential to decline fees these systems. A new generation of AD therapies are passive anti-amyloid immunotherapies that modify the course of the disease. It is expected that only 13% of people with MCI and 17% with mild dementia are eligible for therapy. The task of these products is cleansing the brain from Beta amyloid (Aß) deposits during 18 months. According to the words of producers, therapy allows slowing the decline of executive functions, maintaining social cognition and preserving short-term and working memory. Therapy has side effects which can worse patient health condition. Here we ask: "Where we go wrong and why proper communication with stakeholders regarding anti-amyloid therapies is important? What after antiamyloid therapy?”
Clinical and Encephalographic Features of Epilepsy in Patients with Angelman Syndrome in Crimea
Over the past decade, the number of patients with Angelman syndrome and epilepsy has increased. It is important to diagnose this disease at an early age and promptly begin treatment and rehabilitation measures that will improve the quality of life and social adaptation of patients. The article discusses the clinical characteristics, results of additional research methods and therapeutic approaches in children with Angelman syndrome and epilepsy. Special attention is paid to the clinical and electroencephalographic characteristics of epilepsy in patients with Angelman syndrome using the example of clinical cases of Angelman syndrome and epilepsy in Crimea.
Development of Halogenated Indole-Based Chalcones as New Class of MAO-Inhibitors
The design and synthesis of chalcones based on halogenated indole are the main topics of this investigation. Ten derivatives were synthesized by introducing halogen substitutions (F, Cl, Br) at the aromatic B ring's ortho, meta, and para positions. (I-1 to I-10). These compounds' in vitro inhibitory activity towards monoamine oxidases was subsequently determined. Among them, compound I-2 exhibited potent MAO-A inhibition with an IC50 of 0.823±0.045 μM, while compound I-4, with an IC50 of 0.014 ±0.008 μ, showed excellent MAO-B inhibition implying that MAO-B selectivity is improved by parachloro substitution. To assess Central Nervous System (CNS) drug-likeness, the lead molecules were subjected to PAMPA method. The results showed that compound I-2 displayed significant CNS permeability with a Pe value exceeding 4.0 × 10-6 cm/s. Molecular docking revealed that compounds I-2 and I-4 exhibited unique binding interactions compared with the reference drug safinamide, including π-π stacking with TYR-398 and hydrogen bonding with CYS-171, while retaining a conserved hydrogen bond with GLN-206. In silico pharmacokinetic studies further indicated that I-2 and I-4 possess favorable properties, including effective Blood-Brain Barrier (BBB) penetration. Considering these findings, halogenated indole-based chalcones, particularly compounds I-2 and I-4, present themselves as noteworthy lead candidates for addressing neurodegenerative diseases.
Plant Polyprenols Disrupt the IP3R-GRP75-VDAC-MCU Axis to Restore Mitochondrial Motility Defects Associated with Alzheimer’s Disease
Standardized Plant Polyprenols (SPP) were shown to ameliorate cognitive function in a rat model of Alzheimer’s Disease (AD) but we lack understanding of its mechanism of action. The increasing prevalence of AD with age makes it a major health burden in economically developed countries. Mitochondria dysfunctions are highly associated with the pathophysiology of AD. We aimed at better understanding the biological processes by which SPP target mitochondrial behavior and function to improve AD-associated phenotype in a patient-derived cell model. We found that SPP dose-dependently rescued AD-associated defects in mitochondrial motility, restoring docking capabilities in the “sentry” mitochondrial sub-population. SPP also restored mitochondrial bioenergetics, particularly increasing ATP production from the mitochondrial electron transfer chain. Rescue of the mitochondrial motility phenotype was independent from the SPP-mediated increase in de novo protein synthesis and reduced EIF2α activation. Instead we found that SPP modulated MAMs occurrence & signaling, engaged in the control of mitochondrial motility by modulating Ca2+ flux and ER-stress, both processes being impaired in AD. SPP limited the interactions between SERCA1 and the IP3R-GRP75-VDAC-MCU axis, which controlled mitochondrial Ca2+ flux. Disruption of the IP3R-GRP75-VDAC-MCU axis at MAMs by SPP provided a rationale for the control of mitochondrial movements and suggested a mechanism by which SPP increased bioenergetics efficiency and restored ATP production in AD-cells. Other biological processes that may explain SPP activity were discussed including the possibility that the TRACK-Miro interaction may be involved. Our data support clinical testing of SPP as a food supplement to sustain cognitive function in the elderly.
Mitochondria-ER Associated Membrane (MAM)
Spontaneous CSF Leakage Leading to Symptomatic Improvement in a Patient with Normal Pressure Hydrocephalus: A Case Report
Normal Pressure Hydrocephalus (NPH) is a reversible cause of dementia that often responds to Cerebrospinal Fluid (CSF) drainage. Spontaneous CSF leakage is rare in this setting. We report a 79-year-old man with urinary incontinence, gait disturbance, and cognitive decline, diagnosed with probable NPH. Serial lumbar punctures led to marked improvement. During a treatment delay due to the COVID-19 pandemic, he developed spontaneous CSF rhinorrhea, which was followed by further symptomatic relief. This case suggests that spontaneous CSF leakage may temporarily replicate the therapeutic effects of CSF drainage, offering insight into symptom fluctuation and potential diagnostic markers in NPH.
A Breakthrough in Stroke Rehabilitation: Non-Invasive Biophoton Therapy Promotes Neurofunctional Recovery in Chronic Stroke Patients
Background: Effective treatments for chronic stroke remain a critical unmet medical need. Conventional rehabilitation approaches often yield limited functional recovery, especially in patients with long-standing deficits. Emerging evidence suggests that biophoton-based therapies may offer a novel, noninvasive solution to support neuroregeneration. Objective: To evaluate the therapeutic efficacy and safety of Automatic Biophoton Generators (ABGs) in patients with chronic stroke using validated clinical, neurological, and neurophysiological outcome measures. Methods: A randomized, triple-blind, placebo-controlled clinical trial was conducted with 46 chronic stroke patients who received either active ABG treatment (n = 26) or placebo devices (n = 20) over two weeks. Participants in the placebo group were later crossed over to receive active treatment for an additional four weeks. Each treatment group received therapy with 4 ABGs placed around a hotel bed. Stroke recovery was assessed using the Stroke Impact Scale (SIS), SF-36 quality-of-life survey, clinician-led neurological examinations, and quantitative Electroencephalography (qEEG) with Event- Related Potentials (ERP). Additional evaluations included 3D Non-Linear Scanning (3D-NLS) for energetic brain imaging and Bio-Well analysis for organ and meridian energy coherence. Results: Biophoton therapy resulted in statistically significant improvements in SIS scores, stroke recovery rate, neurological exam scores, and quality-oflife measures (p < 0.01). qEEG revealed increased posterior alpha frequencies, reduced theta/beta ratios, and improved ERP latencies, indicating enhanced attention, memory processing, and cognitive speed. 3D-NLS imaging showed rapid cortical reactivation and restored hemispheric balance after only 6 days of therapy. Bio-Well analysis demonstrated systemic energy restoration across the brain, cardiovascular system, and endocrine organs. No adverse events were reported. Conclusion: This study provides strong clinical and neurophysiological evidence that ABG-based biophoton therapy significantly improves functional outcomes in patients with chronic stroke. The therapy was well tolerated and offers a promising, non-invasive approach to address long-standing neurological impairments. These findings support the broader potential of biophoton quantum therapy in treating neurodegenerative and chronic inflammatory disorders.
Multimodal Evidence of Cognitive Restoration in Alzheimer’s Disease Following Biophoton Therapy: A Neurophysiological and Energetic Assessment
Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder marked by cognitive decline, memory loss, and functional impairment. While pharmacologic treatments offer limited symptomatic relief, there is a growing need for non-invasive approaches that promote neurophysiological restoration. Biophoton therapy, a modality using low-level electromagnetic emissions to stimulate biological systems—has shown potential in enhancing brain function. Objective: This study aimed to evaluate cognitive improvements in AD patients following biophoton therapy using a multimodal set of objective neurophysiological and energetic measurement tools. Methods: A cohort of AD patients underwent biophoton therapy for 2 to 4 weeks. Clinical effects were assessed through quantitative electroencephalography (qEEG) and event-related potentials (ERP) using the BrainView Neurotherapy Platform. Additional objective evaluations included 3D Non-Linear Scanning Diagnostics (3D-NLS) for energetic brain mapping, the Bio-Well GDV Camera 3.0 for electromagnetic field coherence, and the FALCON/QUAD Express Doppler ultrasound system to assess vascular health. Data were collected at baseline and at regular intervals to monitor changes in attention, working memory, and cortical activation patterns. Results: A clinical study demonstrated that biophoton therapy led to significant cognitive improvement within 4 weeks in patients with moderate to severe Alzheimer’s disease. qEEG revealed significant increases in posterior peak frequencies and reductions in theta/beta ratios, indicating improved attentional control and cortical activation. ERP latency (N400) decreased, suggesting faster cognitive processing. Frontal alpha asymmetry shifted toward a balanced or positive profile, reflective of mood stabilization. 3D-NLS imaging showed a reduction in compensatory burdens and complete resolution of nidus of defeat zones. Bio-Well analysis indicated increased systemic energy coherence, while vascular assessments demonstrated improved arterial elasticity and cerebral circulation. Conclusion: Biophoton therapy was associated with measurable improvements in cognitive and emotional biomarkers in patients with Alzheimer’s disease. The use of multiple objective assessment tools, including electrophysiological, energetic, and vascular measures—validates these clinical findings and supports further investigation into biophoton therapy as a non-invasive modality for neurocognitive rehabilitation.
Neurophysiological Grading Tool of Ulnar Nerve Entrapment Across Elbow: Revision and Corrections
Ulnar Nerve Entrapment Across the Elbow (UNEAE) is the second most common entrapment of the hand after carpal tunnel syndrome. There are few gradings available for UNEAE with their limitations. The aim of this research is to establish, using the best available evidence, a clinically appropriate revision of the current ulnar nerve conduction grading tool and to evaluate its effectiveness in terms of acceptability, without any invasive tests. To make correction in the research papers which was highlighted in different conferences in recent year? To compare the recording from the First Dorsal Interosseous (FDI) muscles with the Abductor Digiti Minimi (ADM) muscle to see which muscle is more sensitive and shows early changes in ulnar nerve entrapment. To compare the significance of amplitude, drop and conduction block across elbow in terms of abnormality. The revised scale is designed from a clinical physiologist's perspective and based on the numerical values of nerve conduction findings. It could also assist surgeons to use this as a tool for interventional prediction. The proposed revised grading system is based on more nuanced, descriptive categories, ranging from "normal, "early, "mild, "moderate, "severe," and "complete" absence. An additional category of clinical grading is therefore proposed. Method: Retrospect data was collected based on the extensive and detailed grading system previously described by Padua including hands skin temperature. The tests were performed by a qualified Clinical Physiologist (Neurophysiology) using a Keypoint 9033A07 machine, used in line with departmental protocol (peripheral protocol). The Association of Neurophysiological Scientists (ANS) and British Society of Clinical Neurophysiology (BSCN) (2014) guidelines and minimum standards for the practice of clinical neurophysiology in the United Kingdom were followed including recording the temperature. All data was recorded numerically to ensure methodological reliability. Result: Retrospect data was collected over the course of one year (2017). A total of 190 patients were involved in this study. A collection of 278 consecutive symptomatic hands was tested for conduction block across the elbow while recording from the first dorsal interosseous FDI muscles. Out of the 278 samples, 201 hands were graded as having normal conduction velocity: 9 hands showed early changes, 51 hands showed mild changes, 14 hands showed moderate changes, 2 hands showed severe changes, and 1 hand showed complete absence or no response from the wrist and across the elbow. Additional studies were carried out from the abductor digiti minimi (ADM) muscles for those patients who showed conduction block across the elbow while recording from the FDI muscles. Only 57 patients underwent a nerve conduction study for ADM. 77 symptomatic hands were tested for conduction block in the ADM muscle. 18 hands were graded as normal; 9 hands showed early changes; 48 hands showed mild changes; 10 hands showed moderate changes; and 1 hand showed complete absence or no response from the wrist and across the elbow. Out of 278 hands, 266 hands were graded as having normal amplitude across the elbow while recording from FDI muscles; 7 hands showed early changes in amplitude; 1 hand showed moderate amplitude change; 4 hands showed severe amplitude changes. Out of 77 abnormal hands, 73 hands showed normal amplitude across the elbow while recording from ADM muscles; 2 hands showed mild changes; 1 hand showed a moderate change; and 1 hand showed complete absence or no response from the wrist and across the elbow. Conclusion: Result shows that FDI is more sensitive in comparison to ADM to record early changes in ulnar nerve entrapment across the elbow. In addition, it shows that a drop in amplitude is not as significant when compared to a conduction block across the elbow.
Functionalized Selenium Nanoparticles with Baicalin-Myricetin with Neuroprotective Effect for Alzheimer's Disease
Background: AD disease involves deposition of Aβ amyloid in the mitochondria of cells, reducing consumption of glucose by neurons reducing enzyme functions. Contemporary drugs therapy for AD are unable to alleviate this disease; since in the short term it only produced symptomatic alleviation, thus is necessary to develop new drugs with curative effects. Objective: To determine the neuroprotective effect of flavonoids combined with selenium nanoparticles (EM@Se). Methods: Was successfully synthesized selenium nanoparticles of Baicalin-Myricetin, characterized using different techniques: UV/vis, Fourier-transforminfrared spectroscopy, transmission electron microscopy, DTS, energy dispersive X-ray, vitro drug release, cytotoxicity and in vivo in AD induced by AlCl3. Results: EM@Se showed optimum particle size (94.52 nm), polydispersity index (0.153), and zeta potential (−-30.3 mv) with high entrapment efficiency (88. 7%) NPs achieve significantly maintain EM in vitro release, possesses low cytotoxicity in RAW264.7 macrophage cells. In vivo experiments restore cognitive function to the normal level, reducing hippocampal oxidative damage and decrease Aβ amyloid in plasma. Conclusion: This study provides evidence of the neuroprotective effects of flavonoids combined with nanoparticles.
We already know a lot about the world around us and, in general terms, understand how things work. Of course, some problems have not yet been solved: the behavior of black holes, the mysteries of quantum entanglement, the transparency of dark matter. It is not clear how life aroses from the dust. However, we hope to eventually understand everything that we do not yet understand, be the cause we believe in the power of our minds. But the problem of the mind itself stands apart. There is nothing more complex in the world than consciousness. Here we have to comprehend ourselves and it is not entirely obvious that this is possible. Let's say the meat grinder is quite primitive, but she doesn't know it. It can be admitted that there is not even a scientific definition of consciousness yet.
DTI and AI in Alzheimer’s Disease Research: A Commentary
Alzheimer's Disease (AD) is a leading cause of cognitive decline in older adults, yet early diagnosis remains a major challenge. Diffusion Tensor Imaging (DTI) has emerged as a promising neuroimaging technique for assessing white matter integrity, a key factor in Alzheimer's progression. This commentary explores the intersection of DTI and Artificial Intelligence (AI), highlighting how advanced machine learning (ML) and deep learning (DL) algorithms are being utilized to process DTI data and improve AD diagnosis. AI models, including Convolutional Neural Networks (CNNs) and Recurrent Neural Networks (RNNs), have demonstrated significant success in predicting AD progression, identifying disease subtypes, and differentiating Alzheimer's from other dementias. Automated Fiber Quantification (AFQ) also plays a critical role in analyzing white matter disruptions associated with AD. This synergistic approach between DTI and AI is advancing early detection efforts and paving the way for more precise and personalized AD diagnoses, ultimately enhancing clinical outcomes and improving our understanding of Alzheimer’s pathology